Palatin Technologies, Inc. (NYSE:PTN) is a US based biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of various diseases. Very active in SBIR in the firm's early years (1986-2022) but not recently, the company's lead product is Bremelanotide, an as needed subcutaneous injectable peptide melanocortin receptor agonist currently in the Phase III clinical studies for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). The firm's drug development programs also include Melanocortin receptor-4 (MC4r) peptides and small molecule agonists that are under the preclinical trials for the treatment of conditions responsive to MC4r activation, including female sexual dysfunction, HSDD, erectile dysfunction, obesity, and diabetes; and Melanocortin receptor-1 peptide agonists, which are under preclinical studies for the treatment of inflammatory and dermatologic disease indications, as well as other Melanocortin receptors. In addition, the company is involved in the development of natriuretic peptide receptor-specific programs, including PL-3994, a natriuretic peptide receptor-A, which is in Phase II clinical studies for treatment of heart failure, acute exacerbations of asthma, and refractory hypertension.
